News
CLYM
11.01
+7.00%
0.72
Analysts Have Conflicting Sentiments on These Healthcare Companies: Gilead Sciences (GILD), Climb Bio (CLYM) and Legend Biotech (LEGN)
TipRanks · 9h ago
Climb Bio’s Buy Rating Reiterated as Pipeline Catalysts Advance; Price Target Unchanged at $30
TipRanks · 23h ago
Weekly Report: what happened at CLYM last week (1102-1106)?
Weekly Report · 1d ago
Climb Bio Is Maintained at Outperform by Wedbush
Dow Jones · 3d ago
Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $27
Benzinga · 3d ago
Climb Bio price target raised to $27 from $25 at Wedbush
TipRanks · 3d ago
Climb Bio files automatic mixed securities shelf
TipRanks · 4d ago
Climb Bio Non-GAAP EPS of -$0.18 beats by $0.02
Seeking Alpha · 4d ago
Climb Bio Reports Third-Quarter Results and Clinical Updates
TipRanks · 4d ago
Climb Bio Q3 EPS $(0.18) Beats $(0.20) Estimate
Benzinga · 4d ago
*Climb Bio 3Q Loss $14.6M >CLYM
Dow Jones · 4d ago
*Climb Bio 3Q Loss/Shr 18c >CLYM
Dow Jones · 4d ago
Press Release: Climb Bio Reports Third Quarter -2-
Dow Jones · 4d ago
Press Release: Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
Dow Jones · 4d ago
Climb Bio To Present New Clinical Data For Budoprutug In Immune Thrombocytopenia At 68th ASH Annual Meeting And Exposition
Benzinga · 5d ago
Weekly Report: what happened at CLYM last week (1026-1030)?
Weekly Report · 11/02 09:42
Climb Bio Price Target Maintained With a $32.00/Share by BTIG
Dow Jones · 10/27 10:47
BTIG Reiterates Buy on Climb Bio, Maintains $32 Price Target
Benzinga · 10/27 09:52
Climb Bio management to meet with Truist
TipRanks · 10/26 16:15
Wedbush Remains a Buy on Climb Bio (CLYM)
TipRanks · 10/26 12:28
More
Webull provides a variety of real-time CLYM stock news. You can receive the latest news about Climb Bio through multiple platforms. This information may help you make smarter investment decisions.
About CLYM
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.